Major Acquisition in Rare Disease Space
BioCryst Pharmaceuticals, which has already built out a commercial footprint around its oral HAE drug Orladeyo and is looking ahead to its next growth driver, has agreed to acquire Astria Therapeutics in a $700 million deal.
Astria brings with it a phase 3 hereditary angioedema (HAE) candidate positioned to compete with Takeda’s Takhzyro, giving BioCryst a shot at expanding its presence in the space.
Strategic Growth and Market Expansion
BioCryst, headquartered in North Carolina, already markets Orladeyo, an oral, once-daily capsule cleared in 2020 to prevent HAE attacks in patients aged 12 and up. The company expects the drug to reach about $1 billion in annual peak sales by the end of the decade and has been channeling resources into R&D and business development to line up what comes next.
The search has led to a deal to purchase Astria at $13 per share, which is a 53% premium compared to the company’s closing price on Monday.
A New Era for HAE Treatment
BioCryst is acquiring Astria to gain access to navenibart, a long-acting injectable that blocks plasma kallikrein. Takeda already markets a similar injectable, the aforementioned Takhzyro, which is given every two to four weeks.
During an investor call about the acquisition, Charlie Gayer, BioCryst’s chief commercial officer, noted that around 5,000 people in the U.S. with HAE rely on current injectable preventive treatments, even though they involve frequent and sometimes painful dosing.
Referring to navenibart, Gayer said it would be incredible if patients could manage their attacks just as effectively with a painless injection given only a few times a year – two to four doses instead of a dozen or even two dozen annually. He said both patients with HAE and their doctors view infrequent dosing as the key unmet need, and that an every-three-month regimen is seen as the point at which many would consider switching therapies. That, he said, is where navenibart can really shine.
Promising Clinical Data and Future Outlook
Early signs that navenibart fits what BioCryst is looking for come from an open-label study that reported results in June. Astria reported a 95% average reduction in monthly attack rates with dosing every three months, and an 86% drop in the group treated every six months. According to Gayer, hitting the three-month schedule is the key objective, and proving that six-month dosing works would simply be an added bonus.
Astria is already involved in a phase 3 study evaluating both dosing schedules, with patient enrollment kicking off this year. Initial results are expected in early 2027. That timeline shaped Gayer’s view that navenibart will probably be the first HAE therapy to debut with the three-month dosing interval that BioCryst sees as critical for convincing patients to move away from Takhzyro.
Should navenibart get the nod, BioCryst plans to leverage the commercial infrastructure it originally established for Orladeyo to roll out the new therapy. Because the launch would require minimal additional spending and is expected to coincide with the point at which Orladeyo sales level off, CFO Babar Ghias said he believes navenibart could “supercharge” the company’s earnings growth well into the 2030s.
The acquisition of Astria not only strengthens BioCryst’s HAE portfolio but also signals the company’s ambition to become a leader in the rare disease arena. By combining an oral therapy (Orladeyo) with a potentially best-in-class injectable (navenibart), BioCryst positions itself to offer a full suite of treatment options.
Over time, the company may explore further synergies — for instance, optimizing patient stratification, leveraging real-world data to support differentiated dosing, or expanding into adjacent rare disease indications where its platform and commercial infrastructure can scale. If BioCryst successfully integrates Astria’s assets and demonstrates navenibart’s superior tolerability and efficacy, the deal could set a template for value creation in the rare disease M&A space.
